29 EMMONS DRIVE, PRINCETON, NJ
Soligenix, Inc. Increases Offering Amount by $2.5 Million Under Sales Agreement
News
Soligenix, Inc. Increases Offering Amount by $2,956,000 Under Sales Agreement
Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Other Events
Soligenix, Inc. Enters At Market Issuance Sales Agreement for $3.45M
Soligenix Regains Compliance with Nasdaq Shareholders' Equity Requirement
Material Contracts, Other Events
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload